Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fischer Medical VenturesBOM:524743 +1.55%40 Altman Z-Score is 6.42 as of Jul. 18, 2026, which is 12740% above its 10-year median of 0.05. GuruFocus rates BOM:524743 with a GF Score™ of 40/100 and a GF Value™ of ₹219.55 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 808 Medical Devices & Instruments companies, Fischer Medical Ventures ranks better than 71.29% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 6.32 is strong.
Fischer Medical Ventures has a Altman Z-Score of 6.42, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Fischer Medical Ventures's Altman Z-Score or its related term are showing as below:
BOM:524743'
s Altman Z-Score Range Over the Past 10 Years
Min: -134.63 Med: 0.05 Max: 386.34
Current: 6.32
During the past 13 years, Fischer Medical Ventures's highest Altman Z-Score was 386.34. The lowest was -134.63. And the median was 0.05.
Fischer Medical Ventures (BOM:524743) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524743 vs ABT, SYK, MDT: Altman Z-Score Comparison
For the Medical Devices subindustry, Fischer Medical Ventures's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fischer Medical Ventures Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fischer Medical Ventures's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Fischer Medical Ventures's Altman Z-Score falls into.
Fischer Medical Ventures Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Fischer Medical Ventures (BOM:524743) has a Altman Z-Score of 6.42 as of Jul. 18, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Fischer Medical Ventures and its competitors. This is 12740% above median its historical median of 0.05. According to the industry distribution chart, Fischer Medical Ventures ranks #232 out of 808 companies in the Medical Devices & Instruments industry, placing it in the top 28.7%.
Is Fischer Medical Ventures' Altman Z-Score too high?
Fischer Medical Ventures' current Altman Z-Score of 6.42 is 12740% above median its 10-year median of 0.05. The Medical Devices & Instruments industry median Altman Z-Score is 3.02. Fischer Medical Ventures' value of 6.42 is 112.6% above this industry median. Based on the distribution chart, Fischer Medical Ventures ranks #232 out of 808 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Fischer Medical Ventures has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fischer Medical Ventures' Altman Z-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Fischer Medical Ventures ranks #232 out of 808 companies for Altman Z-Score. This puts Fischer Medical Ventures in the upper half of its industry. The industry median Altman Z-Score is 3.02. Fischer Medical Ventures' value of 6.42 is 112.6% above this benchmark. While the company's 10-year median is 0.05 vs. the industry median of 3.02, Fischer Medical Ventures has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 3.02, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fischer Medical Ventures's current Altman Z-Score of 6.42 is 112.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Fischer Medical Ventures and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fischer Medical Ventures's current Altman Z-Score is 6.42, which is 12740% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fischer Medical Ventures stock overvalued right now?
Based on GuruFocus' analysis, Fischer Medical Ventures (BOM:524743) is currently considered Possible Value Trap. The stock's GF Value™ is ₹219.55, compared to a current price of ₹39.41 — trading 82% below its estimated fair value. The current Altman Z-Score is 6.42, which is 12740% above median its 10-year median of 0.05 and 112.6% above the Medical Devices & Instruments industry median of 3.02. Fischer Medical Ventures' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Fischer Medical Ventures (BOM:524743), the current Altman Z-Score is 6.42 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fischer Medical Ventures (BOM:524743) Overvalued in 2026?
Based on GuruFocus' analysis, Fischer Medical Ventures stock appears to be undervalued.
The current stock price of ₹39.41 is trading 82% below its estimated GF Value™ of ₹219.55.
GuruFocus considers Fischer Medical Ventures to be Possible Value Trap.
Key valuation signals for BOM:524743:
Altman Z-Score: 6.42 (12740% above median its 10-year median of 0.05)
GF Value™: ₹219.55 vs. price of ₹39.41 (82% below fair value)
Industry Position: 112.6% above the Medical Devices & Instruments median (#232 of 808)
No single metric tells the full story. See the BOM:524743 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fischer Medical Ventures Ltd is engaged in developing and trading of Medical Equipment including cutting-edge Magnetic Resonance Imaging (MRI) systems in India.
40GF Score
Get the complete analysis for BOM:524743
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524743 has been successfully added to your 
